33 related articles for article (PubMed ID: 33907121)
1. Influence of sex on outcomes of liver transplantation for hepatocellular carcinoma: a multicenter cohort study in China.
Chen J; Yang Z; Gao F; Zhou Z; Chen J; Lu D; Wang K; Sui M; Wang Z; Guo W; Lyu G; Qi H; Cai J; Yang J; Zheng S; Xu X
Cancer Biol Med; 2024 Feb; 21(4):347-62. PubMed ID: 38425217
[TBL] [Abstract][Full Text] [Related]
2. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8
Peña-Asensio J; Calvo H; Torralba M; Miquel J; Sanz-de-Villalobos E; Larrubia JR
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33923463
[TBL] [Abstract][Full Text] [Related]
4. Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer.
Albrecht T; Brinkmann F; Albrecht M; Lonsdorf AS; Mehrabi A; Hoffmann K; Kulu Y; Charbel A; Vogel MN; Rupp C; Köhler B; Springfeld C; Schirmacher P; Roessler S; Goeppert B
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33918309
[TBL] [Abstract][Full Text] [Related]
5. Optimal Timing of Radiotherapy after Incomplete Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.
Byun HK; Kim N; Seong J
Yonsei Med J; 2021 May; 62(5):409-416. PubMed ID: 33908211
[TBL] [Abstract][Full Text] [Related]
6. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine.
Moldogazieva NT; Zavadskiy SP; Terentiev AA
Cancer Genomics Proteomics; 2021; 18(3 Suppl):369-383. PubMed ID: 33994362
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world.
Xie D; Sun Q; Wang X; Zhou J; Fan J; Ren Z; Gao Q
Ann Transl Med; 2021 Apr; 9(8):652. PubMed ID: 33987350
[TBL] [Abstract][Full Text] [Related]
8. Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort.
von Felden J; Karkmann K; Ittrich H; Gil-Ibanez I; Fründt T; Krause J; Lohse AW; Wege H; Schulze K
Visc Med; 2021 Mar; 37(2):87-93. PubMed ID: 33981749
[TBL] [Abstract][Full Text] [Related]
9. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study.
Mähringer-Kunz A; Steinle V; Kloeckner R; Schotten S; Hahn F; Schmidtmann I; Hinrichs JB; Düber C; Galle PR; Lang H; Weinmann A
PLoS One; 2021; 16(5):e0249426. PubMed ID: 33961627
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC.
Dong Y; Wong JSL; Sugimura R; Lam KO; Li B; Kwok GGW; Leung R; Chiu JWY; Cheung TT; Yau T
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33919570
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of an autophagy-related lncRNA signature in hepatocellular carcinoma.
Yang S; Zhou Y; Zhang X; Wang L; Fu J; Zhao X; Yang L
BMC Bioinformatics; 2021 Apr; 22(1):217. PubMed ID: 33910497
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
Front Immunol; 2021; 12():653437. PubMed ID: 34349755
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of serum soluble PD-1 and ADV score for living donor liver transplantation in patients with previously untreated hepatocellular carcinoma.
Hwang S; Lee KJ; Moon DB; Song GW; Jung DH; Kim YK; Yang H; An DE; Lee S; Lee SG
Ann Surg Treat Res; 2022 Jan; 102(1):46-54. PubMed ID: 35071119
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.
Xue JS; Liu H; Meng GX; Ding ZN; Yan LJ; Yao SY; Li HC; Dong ZR; Chen ZQ; Hong JG; Li T
Cancer Immunol Immunother; 2022 Jul; 71(7):1633-1644. PubMed ID: 34750662
[TBL] [Abstract][Full Text] [Related]
15. Absence of association between pretransplant serum soluble programmed death protein-1 level and prognosis following living donor liver transplantation in patients with hepatocellular carcinoma.
Na BG; Kim YK; Hwang S; Lee KJ; Park GC; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH; Yang H; Yoon YI; Tak E; Park YH; Lee SG
Medicine (Baltimore); 2021 Apr; 100(17):e25640. PubMed ID: 33907121
[TBL] [Abstract][Full Text] [Related]
16. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
17. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
